Cargando…

Routine vaccination against MenB: Considerations for implementation

Effective polysaccharide(conjugate) vaccines against Neisseria meningitidis serogroups A, C, W, and Y have been widely used, but serogroup B meningococci remain a major cause of severe invasive meningococcal disease (IMD) worldwide, especially in infants. Recently, a vaccine, 4CMenB (Bexsero(®)), co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaaijk, Patricia, van der Ende, Arie, Luytjes, Willem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185901/
https://www.ncbi.nlm.nih.gov/pubmed/24141209
http://dx.doi.org/10.4161/hv.26816
_version_ 1782337981555671040
author Kaaijk, Patricia
van der Ende, Arie
Luytjes, Willem
author_facet Kaaijk, Patricia
van der Ende, Arie
Luytjes, Willem
author_sort Kaaijk, Patricia
collection PubMed
description Effective polysaccharide(conjugate) vaccines against Neisseria meningitidis serogroups A, C, W, and Y have been widely used, but serogroup B meningococci remain a major cause of severe invasive meningococcal disease (IMD) worldwide, especially in infants. Recently, a vaccine, 4CMenB (Bexsero(®)), containing three recombinant proteins, and outer membrane vesicles (OMV) derived from a serogroup B meningococcal strain (MenB) has been licensed in Europe and Australia and is indicated for persons aged 2 mo or older. This article discusses what should be considered to enable a successful implementation of a broad coverage MenB vaccine in national immunization programs. Epidemiology data, vaccine characteristics including vaccine coverage, immunogenicity, post-implementation surveillance and costs are relevant aspects that should be taken into account when selecting an appropriate immunization strategy. The potential impact on strain variation and carriage, as well as monitoring vaccine effectiveness, and rare but potentially serious adverse events are points that need to be included in a post-implementation surveillance plan.
format Online
Article
Text
id pubmed-4185901
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41859012015-02-28 Routine vaccination against MenB: Considerations for implementation Kaaijk, Patricia van der Ende, Arie Luytjes, Willem Hum Vaccin Immunother Commentary Effective polysaccharide(conjugate) vaccines against Neisseria meningitidis serogroups A, C, W, and Y have been widely used, but serogroup B meningococci remain a major cause of severe invasive meningococcal disease (IMD) worldwide, especially in infants. Recently, a vaccine, 4CMenB (Bexsero(®)), containing three recombinant proteins, and outer membrane vesicles (OMV) derived from a serogroup B meningococcal strain (MenB) has been licensed in Europe and Australia and is indicated for persons aged 2 mo or older. This article discusses what should be considered to enable a successful implementation of a broad coverage MenB vaccine in national immunization programs. Epidemiology data, vaccine characteristics including vaccine coverage, immunogenicity, post-implementation surveillance and costs are relevant aspects that should be taken into account when selecting an appropriate immunization strategy. The potential impact on strain variation and carriage, as well as monitoring vaccine effectiveness, and rare but potentially serious adverse events are points that need to be included in a post-implementation surveillance plan. Landes Bioscience 2014-02-01 2013-10-18 /pmc/articles/PMC4185901/ /pubmed/24141209 http://dx.doi.org/10.4161/hv.26816 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Commentary
Kaaijk, Patricia
van der Ende, Arie
Luytjes, Willem
Routine vaccination against MenB: Considerations for implementation
title Routine vaccination against MenB: Considerations for implementation
title_full Routine vaccination against MenB: Considerations for implementation
title_fullStr Routine vaccination against MenB: Considerations for implementation
title_full_unstemmed Routine vaccination against MenB: Considerations for implementation
title_short Routine vaccination against MenB: Considerations for implementation
title_sort routine vaccination against menb: considerations for implementation
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185901/
https://www.ncbi.nlm.nih.gov/pubmed/24141209
http://dx.doi.org/10.4161/hv.26816
work_keys_str_mv AT kaaijkpatricia routinevaccinationagainstmenbconsiderationsforimplementation
AT vanderendearie routinevaccinationagainstmenbconsiderationsforimplementation
AT luytjeswillem routinevaccinationagainstmenbconsiderationsforimplementation